Stock Screener App

Gratuito -

Installare

14.97

1.84% 0.27

after-market

Dopo l'orario di chiusura: 14.68 -0.29 -1.94%

4 D Molecular Therapeutics Inc (FDMT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria

4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan

4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat

4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn

David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan

HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com

146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada

4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat

4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media

4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat

4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat

4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan

Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat

Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail

4DMT Announces New Employment Inducement Grants - The Manila Times

H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

4D Molecular Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear - GuruFocus

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results - MarketBeat

FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise - Stock Titan

4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss - Stock Titan

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat

4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat

4D Molecular Therapeutics Inc (FDMT) Stock News Today - TradingKey

4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

4D Molecular Therapeutics Inc expected to post a loss of $1.02 a shareEarnings Preview - TradingView

4D Molecular Therapeutics Inc (FDMT) Stock Price, Trades & News - GuruFocus

4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan - Stock Titan

Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History - GuruFocus

4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares - GuruFocus

FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades - Stock Titan

David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat

4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan - Stock Titan

Enterprise value to revenue forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView

Form 144 4D Molecular Therapeutics For: 4 August By Investing.com - Investing.com Nigeria

FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares - Stock Titan

Janus Henderson Group PLC Acquires 611,276 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat

4D Molecular Therapeutics (NASDAQ:FDMT) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

4D Molecular Therapeutics, Inc. Revenue Breakdown – NASDAQ:FDMT - TradingView

Exome Asset Management LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat

4D Molecular Therapeutics Inc (FDMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

4D Molecular Therapeutics Inc (FDMT) Income Statement - tradingkey.com

4D Molecular Therapeutics Inc (FDMT) Valuation: PE, PB & Fair Value Analysis - TradingKey

FDMT|4D Molecular Therapeutics Inc|Price:10.380|Chg%:+0.310 - TradingKey

4D Molecular Therapeutics Inc (FDMT) Balance Sheet - TradingKey

4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

FDMT|4D Molecular Therapeutics Inc|Price:16.530|Chg%:+1.810 - TradingKey

4D Molecular Therapeutics Inc (FDMT) Institutional Confidence - TradingKey

4D Molecular Therapeutics Inc (FDMT) Cash Flow - TradingKey

4D Molecular Therapeutics (FDMT) Slips Over 2% – Key Levels Under ScrutinyTPO Profile - vinanet.vn

4D Molecular Therapeutics Inc - TradingKey

4D Molecular Therapeutics Inc (FDMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

FDMT|4D Molecular Therapeutics Inc|Price:10.070|Chg%:-0.310 - TradingKey

4D Molecular releases phase 2 data for wet AMD asset 4D-150 - MSN

BNTX

$103.76

0.86%

INSM

$126.29

0.31%

RPRX

$63.96

0.13%

ALNY

$266.11

0.61%

ONC

$358.26

1.22%

RVMD

$210.02

0.40%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters